Comparative prognostic value of lactate dehydrogenase and neuron-specific enolase in small-cell lung cancer patients treated with platinum-based chemotherapy

Quoix, Élisabeth; Purohit, Ashok; Faller-Beau, M.; Moreau, L.; Oster, J.P.; Pauli, G.

doi:10.1016/s0169-5002(00)00131-8

Cited by 61 publications

(40 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…few side-effects in order to obtain maximum quality of life in ''terminal life'' or new alternative treatments. Our result of the prognostic value of serum LDH levels is in accordance with the literature showing that an elevated serum LDH is a prognostic parameter of short survival in patients with SCLC [30][31][32][33]. When serum LDH was included in the multivariate analysis it was not an independent prognostic variable.…”

Section: Discussionsupporting

confidence: 91%

High serum YKL-40 level in patients with small cell lung cancer is related to early death

et al. 2004

View full text Add to dashboard Cite

Summary YKL-40, a growth factor for connective tissue cells, is secreted by cancer cells and macrophages. Elevated serum YKL-40 in patients with metastatic carcinoma has been associated with poor prognosis. We evaluated serum YKL-40 in 131 patients with small cell lung cancer (SCLC). Twenty-two percent of the patients with limited disease and 40% of the patients with extensive disease had elevated serum YKL-40. The median survival was 5.1 months for patients with elevated serum YKL-40 and 9.0 months for patients with normal serum YKL-40. Patients with elevated serum YKL-40 had increased hazard for death within the first 6 months after the start of chemotherapy compared to patients with normal serum YKL-40 (HR = 2.06, P = 0.009). Multivariate Cox analysis including routine prognostic variables showed that serum YKL-40 (P = 0.02) is independent of prognostic variables for survival within the first 6 months. Studies are needed to determine the function of YKL-40 in SCLC.

show abstract

Section: Discussionsupporting

confidence: 91%

High serum YKL-40 level in patients with small cell lung cancer is related to early death

et al. 2004

View full text Add to dashboard Cite

show abstract

“…An association between decreased serum albumin level and decreased survival has been demonstrated in patients with SCLC (Quoix et al, 2000;Hansen et al, 2010). Similarly serum level of albumin was found to be an independent prognostic factor of survival in our study.…”

Section: Discussionmentioning

confidence: 99%

Is Diabetes Mellitus a Prognostic Factor for Survival in Patients with Small Cell Lung Cancer?

İnal

Kaplan²,

Küçüköner³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…LDH is now recognized as an important prognostic factor (Albain et al, 1990;Sagman et al, 1991;Maestu et al, 1997;Quoix et al, 2000). We could not assess it in our multivariate analysis because of the number of missing values.…”

Section: Discussionmentioning

confidence: 99%

Progress in the management and outcome of small-cell lung cancer in a French region from 1981 to 1994

Lebitasy¹,

Hédelin

Purohit³

et al. 2001

Br J Cancer

View full text Add to dashboard Cite

Summary Recent analyses of series of small-cell lung cancer (SCLC) patients included in clinical trials have shown improved survival over time, but it has been impossible to determine whether this was due to selection biases, stage migration, or true therapeutic improvement. To determine if there has been a true improvement of survival over time, we reviewed the medical records of all consecutive patients diagnosed with SCLC between 1981 and 1994 in the Bas-Rhin in France. Among the 787 patients (median age 63), there was no significant period effect for sex, age, or stage. Staging work-ups became increasingly thorough (significant period effect). The mean number of investigations and of tumour sites detected correlated significantly. The chemotherapy rate increased (from 76.4% in 1981-1983 to 91.7% in 1993-1994, P = 10 -5 ) and mediastinal irradiation decreased (to roughly 25% of patients after 1983). Median survival time increased for the overall population from 6.6 months in 1981-1983 to 11.3 months in 1993-1994 (P = 10 -5 ), for patients with limited disease (LD) from 9.2 (P = 0.002) months to 14.0 months, and for those with extensive (ED) disease from 3.5 months to 9.6 months (P = 10 -5 ). Significant independent prognostic factors were disease extent, clinical trial participation, period, type of chemotherapy, and mediastinal irradiation in LD. Survival time has truly improved as 'state of the art' management of SCLC has changed.

show abstract

Comparative prognostic value of lactate dehydrogenase and neuron-specific enolase in small-cell lung cancer patients treated with platinum-based chemotherapy

Cited by 61 publications

References 23 publications

High serum YKL-40 level in patients with small cell lung cancer is related to early death

High serum YKL-40 level in patients with small cell lung cancer is related to early death

Is Diabetes Mellitus a Prognostic Factor for Survival in Patients with Small Cell Lung Cancer?

Progress in the management and outcome of small-cell lung cancer in a French region from 1981 to 1994

Contact Info

Product

Resources

About